Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9TWR7)

Drug Name

DEHYDROZINGERONE Drug Info

Synonyms

Dehydrozingerone; 1080-12-2; Feruloylmethane; 4-(4-Hydroxy-3-methoxyphenyl)-3-buten-2-one; 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; Vanillalacetone; Dehydro(O)-paradol; MHSK; Dehydrogingerone; Vanylidenacetone; 3-BUTEN-2-ONE, 4-(4-HYDROXY-3-METHOXYPHENYL)-; (O)-Paradol, dehydro-; Vanillidene acetone; 3-Methoxy-4-hydroxybenzalacetone; (O)-Dehydroparadol; (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; 4-Hydroxy-3-methoxystyryl methyl ketone; NSC 5316; NSC 4019; Vanillylidene acetone; UNII-8CJX5I27B7; Vanillylideneacetone

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5354238
ChEBI ID: CHEBI:81361
CAS Number: CAS 1080-12-2
TTD Drug ID: DM9TWR7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Amyloid beta A4 protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[2]
Aducanumab	DM51JW4	Alzheimer disease	8A20	Approved	[3]
Lecanemab	DMW03YD	Alzheimer disease	8A20	Approved	[4]
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[5]
GV-971	DMTMA5W	Alzheimer disease	8A20	Approved in China	[6]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[7]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[8]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[9]
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
4	The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
7	Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
8	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
9	Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)